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Background: GP78 is a membrane-anchored ubiquitin ligase mediating the degradation of 3-hydroxy-3-methyl-
glutaryl-CoA coenzyme A reductase (HMGCR) and Insig-1, which was very essential for the synthesis of cholesterol
process. Cholesterol levels have a causal role in the development of cardiovascular disease. The aim of the present
study was to assess the association between the human gp78 gene polymorphism and coronary artery disease
(CAD) in a Han and Uygur population of China.
Methods: We used two independent case–control studies: a Han population (602 CAD patients and 572control
subjects) and a Uygur population (374 CAD patients and 376control subjects). All CAD patients and controls were
genotyped for the same three single nucleotide polymorphisms (SNPs) (rs731119, rs2617849and rs2440472) of gp78
gene by a Real-time PCR instrument.
Results: In the Han population, for total and men, the distribution of SNP3 (rs2440472) alleles and the dominant model
(AA vs AG + GG) and recessive model (GG vs AG + AA) showed a significant difference between CAD and control
participants (for allele: P = 0.003 and P = 0.002, respectively; for dominant model: P = 0.041 and P = 0.026, respectively;
for recessive model: p = 0.004 and p = 0.004, respectively).The significant difference in both the two models was
retained after adjustment for covariates (for dominant model OR:0.760, 95% confidence interval [CI]:0.584-0.99, P = 0.042;
OR:0.686, 95% CI: 0.498-0.946, P = 0.022, respectively; for recessive model OR: 1.451, 95% CI: 1.067-1.974, P = 0.018; OR:
1.789, 95% CI: 1.219-2.627, P = 0.000). Our data was also assessed via haplotype-based case–control studies. For the Han
population, for total, The G-T-G haplotype in CAD was significantly higher than that in the control group (P = 0.02), and
the G-C-A haplotype in CAD was significantly lower than that in the control group (P = 0.0443), And for man, the G-T-G
haplotype in CAD was significantly higher than that in the control group (P = 0.0048).
Conclusions: The GG genotype and G allele of rs2440472 in gp78 gene could be a risk genetic marker of CAD in Han
population in China.
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The etiology and pathogenesis of coronary artery disease
(CAD) are likely to comprise a multifactorial disorder
resulting from inheritance of several susceptibility genes,
as well as multiple environmental determinants [1,2].
Experimental, genetic, and epidemiologic data support
the concept that an elevated plasma level of low-density* Correspondence: myt-xj@163.com
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unless otherwise stated.lipoprotein (LDL) cholesterol is a primary causal factor
in the pathogenesis of coronary artery disease [3], a main
underlying pathology is atherosclerosis, a process of
cumulative deposition of LDL cholesterol in the arteries
supplying blood to the heart and brain that eventually
leads to impaired or absent blood supply and myocardial
infarction or stroke [4]. Consistent and compelling evi-
dence has demonstrated association between lipid concen-
trations and cardiovascular disease incidence worldwide
[5-7]. HMGCR catalyzes the conversion of 3-hydroxy-3-
methy-lglutaryl coenzyme A ( HMG-CoA ) to mevalonate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Sterol promotes the degradation of HMGCR through the
ubiquitin-proteasome pathway, and therefore slows down
cholesterol biosynthesis [9]. gp78 (also known as autocrine
motility factor receptor [AMFR]), an ER (endoplasmic
reticulum) membrane-anchored ubiquitin ligase, has been
identified as the E3 that ubiquitinates HMGCR [10,11].
Through its transmembrane domain, gp78 interacts with
another ER membrane protein, Insig-1or Insig-2 [11].
When the cholesterol level is low, HMGCR is kept apart
from the Insig-gp78 complex and stabilized. A high level
of sterol promotes the interaction between HMGCR and
Insig-1/-2, which causes the ubiquitination of HMGCR by
gp78 and subsequent degradation [11]. So it has been
hypothesized that gp78 may suppress cholesterol biosyn-
thesis by targeting HMGCR to degradation. Besides
HMGCR, gp78 also mediates the degradation of Insig-1
protein. Destruction of Insig-1 releases its inhibition on
SREBP and stimulates the expression of lipogenic genes.
Thus, gp78 has opposite effects on lipid biosynthesis [12].
Originally, gp78 was identified as the tumor autocrine
motility factor receptor that mediates tumor invasion
and metastasis [13,14]. The transcript for gp78 is widely
expressed in a variety of tissues, and immunoblot ana-
lysis with a monoclonal antibody indicates that an in-
crease in levels of gp78 correlates with the metastatic
potential of a variety of human tumors. GP78 was very
essential for the synthesis of cholesterol process. Choles-
terol levels have a causal role in the development of
cardiovascular disease. The aim of the present study was
to assess the association between the human gp78 gene
and CAD.
Methods
Ethical approval of the study protocol
This study was approved by the Ethics Committee of the
First Affiliated Hospital of Xinjiang Medical University
(Urumqi, China). Written informed consent was obtained
from all participants. All participants explicitly provided
permission for DNA analyses as well as collection of
relevant clinical data. It was conducted according to the
standards of the Declaration of Helsinki.
Subjects
The subjects were from a Han population and a Uygur
population who lived in the Xinjiang Uygur Autono-
mous Region of China. All patients and controls had a
differential diagnosis for chest pain encountered in the
Cardiac Catheterization Laboratory of First Affiliated
Hospital of Xinjiang Medical University from 2006 to
2013. All of the procedures of coronary angiography
were undertaken by highly skilled physicians using the
Judkins approach. The findings of coronary angiography
were interpreted by at least two experienced imagingspecialists and the final diagnosis of CAD was made
according to the angiography report.
We selected randomly 602 Han patients and 374
Uygur patients with CAD and a control group of 572
and 376, respectively, of ethnically and geographically
matched individuals. CAD diagnosed by angiography,
which was defined as the presence of at least one signifi-
cant coronary artery stenosis of ≥50% luminal diameter
on coronary angiography. All control subjects also under-
went a coronary angiogram and have no coronary artery
stenoses and did not show clinical or electrocardiogram
evidence of myocardial infarction (MI) or CAD. Control
subjects were not healthy individuals, some of them have
hypertension, some of them have diabetes mellitus (DM),
some of them have hyperlipidemia, which means the con-
trol group were exposed to the same risk factors of CAD
while the results of coronary angiogram is normal. Data
and information about traditional coronary risk factors,
including hypertension, DM, and smoking, were collected
from all study participants. Hypertension was defined as
having a systolic blood pressure above140 mmHg or/and
diastolic blood pressure above 90 mmHg or any anti-
hypertensive agent used. Diabetes mellitus was diagnosed
according to the criteria of the American Diabetes Associ-
ation [15]. In addition, individuals with fasting plasma
glucose >7.0 mmol/L or with a history of diabetes or treat-
ment with insulin were considered diabetic. Smoking was
classified as smokers (including current and ex-smokers)
or non-smokers. All patients with impaired renal function,
malignancy, connective tissue disease, valvular disease or
chronic inflammatory disease were excluded.
Blood collection and DNA extraction
Fasting Blood samples drawn by venepuncture in the
catheter-room were taken from all participants before car-
diac catheterization. The blood samples were drawn into a
5 ml ethylene diamine tetraacetic acid (EDTA) tube and
centrifuged at 4000 × g for 5 min to separate the plasma
content. Genomic DNA was extracted from the peripheral
leukocytes using standard phenol–chloroform method.
The DNA samples were stored at −80°C until use. While
used, the DNA was diluted to 50 ng/uL concentration.
Genotyping
The gp78 gene spans 64. 08 kb, in this study using the
Haploview 4.2 software and the HapMap phrase II database,
we identified three tag SNPs (rs731119, rs2617842 and
rs2440472) by using minor allele frequency (MAF) ≤0.1
and linkage disequilibrium patterns with r2 ≥ 0.5 as a cut
off. The position of the SNP1, SNP2 and SNP3 (rs731119,
rs2617842 and rs2440472) was by order of increasing
distance from the GP78 gene 5`end [Figure 1].
Genotyping was undertaken using the TaqMan® SNP
Genotyping Assay (Applied Bio systems). The primers
Figure 1 Structure of the human GP78 gene. This gene consists of 14 exons separated by 13 introns. Boxes indicate exons, and lines indicate
introns and intergenic regions. Arrows mark the locations of polymorphisms.
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Assays (ABI) were chosen based on information at the
ABI website (http://myscience.appliedbiosystems.com).
Thermal cycling was done using the Applied Biosys-
tems7900HT Standard Real-Time PCR System. Plates
were read on Sequence Detection Systems (SDS) auto-
mation controller software v2.3 (ABI).PCR amplification
was performed using 2.5 μl of TaqMan Universal Master
Mix, 0.15 μl probes and 1.85 ddH2O in a 6-μl final reac-
tion volume containing 1μlDNA.Thermal cycling condi-
tions were as follows: 95°C for 5 min; 40 cycles of 95°C
for 15 s; and 60°C for 1 min. All 96 wells Plates were
read on Sequence Detection Systems (SDS) automation
controller software v2.3 (ABI).
Biochemical analysis
Serum concentrations of total cholesterol (TC), trigly-
ceride (TG), glucose (Glu), high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), Creatinine (Cr), blood urea nitrogen
(BUN), were measured using standard methods in the
Central Laboratory of First Affiliated Hospital of Xinjiang
Medical University.
Statistical analysis
All continuous variables are expressed as means ± stand-
ard deviation (S.D.). The difference between the CAD
and Control groups was analyzed using an independent-
sample T-Test. The differences in the frequencies of
smoking, hypertension, diabetes mellitus, and GP78 ge-
notypes were analyzed using χ2 test or Fisher’s exact test
where appropriate. Hardy–Weinberg equilibrium was
assessed by χ2 analysis. Logistic regression analyses with
effect ratios (odds ratio [OR] and 95% CI) were used to
assess the contribution of the major risk factors. All stat-
istical analyses were performed using SPSS 17.0 for
Windows (SPSS Institute, Chicago, USA). P-values of
less than 0.05 were considered to statistically significant.Results
Table 1 shows the clinical characteristics of the study
participants. For Han and Uygur population, there was
no significant difference in age between CAD patients
and control subjects it means the study was age-matched
case–control study. In the Han and Uygur population, for
total, men, and women, the plasma concentration of Glu,
and the prevalence of essential hypertension (EH), and
diabetes mellitus (DM), were significantly higher for pa-
tients with CAD than for control participants. In the Han
population, for total and men, body mass index (BMI),and
smoking were significantly higher for patients with CAD
than for control participants. The LCL were significantly
higher for patients with CAD than for control participants
only in the Han population for total. In the Uygur popula-
tion, for total and men the HDL were significantly lower
for patients with CAD than for control participants. The
smoking were significantly higher for patients with CAD
than for control participants in the Uygur population for
total.
Table 2 shows the distribution of genotypes and alleles
of SNP1, SNP2 and SNP3 for the GP78 gene, (Table 2:
Han population; Table 3: Uygur population). The geno-
type distributions for each of the SNPs were in agree-
ment with the predicted Hardy-Weinberg equilibrium
values (data not shown). In the Han population, for total
and man, the distribution of SNP3 (rs2440472) geno-
types showed a significant difference between CAD and
control participants (for total:P = 0.008, for males: P =
0.007). The distribution of SNP3 (rs2440472) alleles and
the dominant model (AA vs AG +GG) and recessive
model (GG vs AG +AA) showed a significant difference
between CAD and control participants (for allele: P =
0.003 and P = 0.002, respectively; for dominant model:
P = 0.041 and P = 0.026, respectively; for recessive model:
p = 0.004 and p = 0.004, respectively). G allele of rs2440472
was significantly higher in CAD patients than in control
participants (total: 48.3% vs 42.2%; men: 48.1% vs 38.9%).
















































































































































































































































































































EH (%) 56.9 46.9 0.001* 54.5 46.0 0.022* 61.2 48.1 0.005* 52.3 39.6 0.001* 49.3 37.3 0.007* 61.1 43 0.006*
DM (%) 26.6 11.7 0.001* 24.0 14.7 0.002* 31.3 7.4 0.000* 18.8 6.4 0.000* 18.8 7.1 0.000* 21.1 5.3 0.000*
Smoke (%) 42.6 35.1 0.00* 69.3 58.1 0.002* 4.2 1.3 0.06 44.9 32.4 0.000* 59.9 53.8 0.17 1.1 0.7 0.74
BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; Glu, glucose; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; EH, essential hypertension; DM, diabetes mellitus.
Continuous variable were expressed as mean ± standard deviation. P value of continuous variables was calculated by independent T-T test.







































Genotype G/G 369 (60.8) 375 (64.1) 0.236 237 (61.2) 227 (63.9) 0.695 132 (60) 148 (64.3) 0.283
A/A 21 (3.5) 26 (4.4) 11 (2.8) 11 (3.1) 10 (4.5) 15 (6.5)
A/G 217 (35.7) 184 (31.5) 139 (35.9) 117 (33) 78 (35.5) 67 (29.1)
Dominant
model
GG 369 (60.8) 375 (64.1) 0.238 237 (61.2) 227 (63.9) 0.447 132 (60) 148 (64.3) 0.342
AG + AA 238 (39.2) 210 (35.9) 150 (38.8) 128 (36.1) 88 (40) 82 (35.7)
Recessive
model
AA 21 (3.5) 26 (4.4) 0.382 11 (2.8) 11 (3.1) 0.837 10 (4.5) 15 (6.5) 0.36
AG + GG 572 (99.83) 455 (100) 376 (97.2) 344 (96.9) 210 (95.5) 215 (93.5)
Additive
model
AG 217 (35.7) 184 (31.5) 0.117 139 (35.9) 117 (33) 0.447 78 (35.5) 67 (29.1) 0.342
GG + AA 390 (64.3) 401 (68.5) 237 (61.2) 227 (63.9) 132 (60) 148 (64.3)
Allele G 955 (78.7) 934 (79.8) 0.484 613 (79.2) 571 (80.4) 0.558 342 (77.7) 363 (78.9) 0.666
A 259 (21.3) 236 (20.2) 161 (20.8) 139 (19.6) 98 (22.3) 97 (21.1)
rs2617849
(SNP2)
Genotype T/T 222 (39.9) 181 (38.8) 0.046 132 (37.8) 102 (31.1) 0.159 90 (43.3) 79 (35.3) 0.234
C/C 74 (13.3) 87 (15.8) 49 (14) 56 (17.1) 25 (12) 31 (13.8)
C/T 261 (46.9) 284 (51.4) 168 (48.1) 170 (51.8) 93 (44.7) 114 (50.9)
Dominant
model
TT 222 (39.9) 181 (38.8) 0.014* 132 (37.8) 102 (31.1) 0.066 90 (43.3) 79 (35.3) 0.89
CC + CT 335 (60.1) 371 (67.2) 217 (62.2) 226 (68.9) 118 (56.7) 145 (64.7)
Recessive
model
CC 74 (13.3) 87 (15.8) 0.242 49 (51.9) 56 (17.1) 0.276 25 (12) 31 (13.8) 0.574
TT + CT 483 (86.7) 465 (84.2) 300 (86) 272 (82.9) 183 (88) 193 (86.2)
Additive
model
CT 261 (46.9) 284 (51.4) 0.126 168 (48.1) 170 (51.8) 0.337 93 (44.7) 114 (50.9) 0.199
CC + TT 296 (53.1) 268 (48.6) 181 (51.9) 158 (48.2) 115 (55.3) 110 (49.1)
Allele C 409 (37.7) 458 (41.5) 0.021* 266 (38.1) 282 (43) 0.068 143 (34.4) 176 (39.3) 0.135
T 705 (63.3) 646 (58.5) 432 (61.9) 374 (57) 273 (65.6) 272 (60.7)
rs2440472
(SNP3)
Genotype A/A 164 (27.2) 187 (32.7) 0.008* 110 (28.4) 123 (36.1) 0.007* 54 (25.2) 64 (27.7) 0.582
G/G 144 (23.9) 98 (17.1) 95 (24.5) 54 (15.8) 49 (22.9) 44 (19)
A/G 294 (48.8) 287 (50.2) 183 (47.2) 164 (48.1) 111 (51.9) 123 (53.2)
Dominant
model
A/A 164 (27.2) 187 (32.7) 0.041* 110 (28.4) 123 (36.1) 0.026* 54 (25.2) 64 (27.7) 0.555
GG + AG 438 (72.8) 385 (67.3) 278 (71.6) 218 (63.9) 160 (74.8) 167 (72.3)
Recessive
model
GG 144 (23.9) 98 (17.1) 0.004* 95 (24.5) 54 (15.8) 0.004* 49 (22.9) 44 (19) 0.318
AA + AG 458 (76.1) 474 (82.9) 293 (75.5) 287 (84.2) 165 (77.1) 187 (81)
Additive
model
AG 294 (48.8) 287 (50.2) 0.647 183 (47.2) 164 (48.1) 0.802 111 (51.9) 123 (53.2) 0.771
AA + GG 308 (51.2) 285 (49.8) 205 (52.8) 177 (51.9) 103 (48.1) 108 (46.8)
Allele A 622 (51.7) 661 (57.8) 0.003* 403 (51.9) 410 (60.1) 0.002* 219 (51.2) 251 (54.3) 0.345
G 582 (48.3) 483 (42.2) 373 (48.1) 272 (39.9) 209 (48.8) 211 (45.7)
CAD, coronary artery disease.
The P value of genotype was calculated by Fisher’s exact test. *P<0.05.
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CAD patients than in control participants (total: 51.7% vs
57.8%; males: 51.9% vs 39.9%). The recessive model (GG
vs AG+AA) of rs2440472 was significantly higher in
CAD patients than in control participants (total: 23.9% vs
17.1%; men: 24.5% vs 15.8%). The dominant model (AA vs
AG+GG)of rs2440472 was significantly lower in CAD pa-
tients than in control participants (total: 27.2% vs 32.7%;
males: 28.4% vs 36.1%). For the Uygur population, thedistribution of the three SNPs genotypes and alleles
showed no significant difference between the CAD pa-
tients and control subjects.
Table 4 shows that multiple logistic regression analyses
were done with Glu, EH, DM, BMI,LDL, and smoking
because these variables were the major confounding fac-
tors for CAD, (Table 4: In dominant model; Table 5: In
recessive model. For total and men, the significant differ-
ence of rs2440472 in both models was retained after

















Genotype G/G 269 (63) 244 (64.4) 0.811 202 (62.7) 146 (63.8) 0.873 67 (63.8) 98 (65.3) 0.968
A/A 18 (4.2) 18 (4.7) 12 (3.7) 10 (4.4) 6 (5.7) 8 (5.3)
A/G 140 (32.8) 117 (30.9) 108 (33.5) 73 (31.9) 32 (30.5) 44 (29.3)
Dominant
model
GG 269 (63) 244 (64.4) 0.684 202 (62.7) 146 (63.8) 0.806 67 (63.8) 98 (65.3) 0.802
AG + AA 158 (37) 135 (35.6) 120 (37.3) 83 (36.2) 38 (36.2) 52 (34.7)
Recessive
model
AA 18 (4.2) 18 (4.7) 0.714 12 (3.7) 10 (4.4) 0.705 6 (5.7) 8 (5.3) 0.895
AG + GG 409 (95.8) 361 (95.3) 310 (96.3) 219 (95.6) 99 (94.3) 142 (94.7)
Additive
model
AG 140 (32.8) 117 (30.9) 0.56 108 (33.5) 73 (31.9) 0.682 32 (30.5) 44 (29.3) 0.844
GG + AA 287 (67.2) 262 (69.1) 214 (66.5) 156 (68.1) 73 (69.5) 106 (70.7)
Allele G 678 (79.4) 605 (79.8) 0.833 512 (79.5) 365 (79.7) 0.938 166 (79) 240 (80) 0.793
A 176 (20.6) 153 (20.2) 132 (20.5) 93 (20.3) 44 (21) 60 (20)
rs2617849
(SNP2)
Genotype T/T 152 (39.7) 128 (35.4) 0.576 120 (42.6) 78 (36.1) 0.346 32 (31.7) 50 (34.2) 0.869
C/C 57 (14.9) 58 (16) 36 (12.8) 31 (14.4) 21 (20.8) 27 (18.5)
C/T 174 (45.4) 176 (48.6) 126 (44.7) 107 (49.5) 48 (47.5) 69 (47.3)
Dominant
model
TT 152 (39.7) 128 (35.4) 0.223 120 (42.6) 78 (36.1) 0.145 32 (31.7) 50 (34.2) 0.674
CC + CT 231 (60.3) 234 (64.6) 162 (57.4) 138 (63.9) 69 (68.3) 96 (65.8)
Recessive
model
CC 57 (14.9) 58 (16) 0.667 36 (12.8) 31 (14.4) 0.607 21 (20.8) 27 (18.5) 0.653
TT + CT 326 (85.1) 304 (84) 246 (87.2) 185 (85.6) 80 (79.2) 119 (81.5)
Additive
model
CT 174 (45.4) 176 (48.6) 0.384 126 (44.7) 107 (49.5) 0.282 48 (47.5) 69 (47.3) 0.967
CC + TT 209 (54.6) 186 (51.4) 156 (55.3) 109 (50.5) 53 (52.5) 77 (52.7)
Allele C 288 (37.6) 292 (40.3) 0.279 198 (35.1) 169 (39.1) 0.193 90 (44.6) 123 (42.1) 0.592
T 478 (62.4) 432 (59.7) 366 (64.9) 263 (60.9) 112 (55.4) 169 (57.9)
rs2440472
(SNP3)
Genotype A/A 85 (22.7) 78 (20.7) 0.269 57 (20.4) 43 (19.1) 0.316 28 (29.5) 35 (23.2) 0.513
G/G 120 (32.1) 106 (28.2) 94 (33.7) 64 (28.4) 26 (27.4) 42 (27.8)
A/G 169 (45.2) 192 (51.1) 128 (45.9) 118 (52.4) 41 (43.2) 74 (49)
Dominant
model
A/A 85 (22.7) 78 (20.7) 0.51 57 (20.4) 43 (19.1) o.712 28 (29.5) 35 (23.2) 0.271
GG + AG 289 (77.3) 298 (79.3) 222 (79.6) 182 (80.9) 67 (70.5) 116 (76.8)
Recessive
model
GG 120 (32.1) 106 (28.2) 0.245 94 (33.7) 64 (28.4) 0.207 26 (27.4) 42 (27.8) 0.939
AA + AG 254 (67.9) 270 (71.8) 185 (66.3) 161 (71.6) 69 (72.6) 109 (72.2)
Additive
model
AG 169 (45.2) 192 (51.1) 0.107 128 (45.9) 118 (52.4) 0.143 41 (43.2) 74 (49) 0.371
AA + GG 205 (54.8) 184 (48.9) 151 (54.1) 107 (47.6) 54 (56.8) 77 (51)
Allele A 339 (45.3) 348 (46.3) 0.71 242 (43.4) 204 (45.3) 0.533 97 (51.1) 144 (47.7) 0.467
G 409 (54.7) 404 (53.7) 316 (56.6) 246 (54.7) 93 (48.9) 158 (52.3)
CAD, coronary artery disease.
The P value of genotype was calculated by Fisher’s exact test. *P<0.05.
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Han population (for dominant model OR: 0.760, 95%
confidence interval [CI]: 0.584-0.99, P = 0.042; OR:0.686,
95% CI: 0.498-0.946, P = 0.022, respectively; for recessive
model OR:1.451, 95% CI: 1.067-1.974, P = 0.018; OR:1.789,
95% CI: 1.219-2.627, P = 0.000, respectively).
Table 6 shows the patterns of linkage disequilibrium in
the GP78 gene with their |D′| and r2 values. All threeSNPs were located in one haplotype block because all
the |D′| values were >0.5.r2 values of the three SNPs
were all <0.5, it means the three SNPs can not replace
each other [16,17]. We then used the three SNPs to
establish haplotypes in Han subjects in order of SNP1-
SNP2-SNP3.
Table 7 shows the distribution of haplotypes in CAD
patient and control participants. We found eight haplotypes
Table 4 Multiple logistic regression analysis for CAD patients and control subjects of Han population in dominent model
Total Men Women
OR 95% CI P OR 95% CI P OR 95% CI P
Dominent model (AA vs AG + GG) 0.76 0.584–0.99 0.042* 0.686 0.498–0.946 0.022* 1.027 0.64–1.647 0.913
Glu 1.1 1.027–1.178 0.006* 1.062 0.974–1.158 0.172 1.152 1.021–1.299 0.021
BMI 1.134 1.086–1.183 0.000* 1.099 1.039–1.162 0.001* 1.182 1.103–1.267 0.000*
EH 1.307 1.024–1.669 0.032* 1.244 0.918–1.685 0.159 1.377 0.9–2.106 0.14
LDL 1.131 1.002–1.277 0.046* 1.045 0.891–1.225 0.59 1.311 1.075–1.6 0.008*
DM 2.185 1.542–3.098 0.000* 1.637 1.07–2.505 0.023* 4.265 2.239–8.123 0.000*
Smoking 1.657 1.295–2.12 0.000* 1.674 1.223–2.291 0.001* 2.259 0.516–9.895 0.28
EH, essential hypertension; DM, diabetes mellitus; CAD, coronary artery disease; BMI, body mass index; Glu, glucose; LDL, low density lipoprotein.
*P<0.05.
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were significantly different between the CAD patients and
the control subjects (all P = 0.001). For total and male,the
frequency of the 001(G-T-G) haplotype was significantly
higher for CAD patients than for control subjects (P =
0.02 and P = 0.0048). In addition, the frequency of the 010
(G-C-A) haplotype was lower in the CAD patients than in
the control subjects in total (P = 0.0443).
Table 8 shows the distribution of genotypes and alleles
of SNP1, SNP2 and SNP3 for the GP78 gene between
the Han and Uygur populations. In the CAD group, for
total and man, the distribution of SNP3 (rs2440472)
genotypes and allele showed a significant difference be-
tween Han and Uygur population (genotypes: for total:
P = 0.008, for males: P = 0.011; allel: for total: P = 0.006,
for males: P = 0.002). In the Control group, for total and
man, the distribution of SNP3 (rs2440472) genotypes
and allele showed a significant difference between Han
and Uygur population (genotypes: for total: P = 0.00, for
males: P = 0.00; allel: for total: P = 0.00, for males: P =
0.00). In the CAD group, GG genotype and G allele of
rs2440472 was significantly higher in Han population
than Uygur population. In the Control group, GG geno-
type and G allele of rs2440472 was significantly lower in
Han population than Uygur population.Table 5 Multiple logistic regression analysis for CAD patients a
Total
OR 95% CI P
Recessive model (GGvsAG + AA) 1.451 1.067–1.974 0.018*
Glu 1.098 1.024–1.177 0.009*
BMI 1.136 1.089–1.185 0.000*
EH 1.311 1.026–1.676 0.03*
LDL 1.214 1.038–1.42 0.015*
DM 2.225 1.565–3.162 0.000*
Smoking 1.633 1.274–2.093 0.000*
EH, essential hypertension; DM, diabetes mellitus; CAD, coronary artery disease; BM
*P<0.05.Discussion
Cholesterol is an essential component of most biological
membranes and is the precursor for synthesis of steroid
hormones and bile acids. However, high levels of choles-
terol cause severe problems including coronary heart
disease [18]. Cholesterol is synthesized from acetyl-CoA
through a cascade of enzymatic reactions. The biosyn-
thesis of cholesterol is tightly regulated, mainly through
two feedback regulatory mechanisms: sterol-regulated
degradation of HMG-CoA reductase (HMGCR) and
maturation of sterol-regulatory element-binding protein
(SREBP) [19]. Sterol-regulated degradation of 3-hydroxy-
3-methy-lglutaryl coenzyme A reductase (HMGCR) is a
rapid feedback regulatory mechanism by which cell sem-
ploy to control the cholesterol biosynthesis. This process
is initiated by the sterol induced interaction between
HMGCR and Insig-1/gp78, a membrane-bound ubiqui-
tin ligase complex [20]. When the concentration of cel-
lular sterol is high, the membrane domain of HMGCR
can sense the excessive sterols and the whole protein is
rapidly degraded, therefore the cholesterol biosynthesis
is shut down [21]. This sterol promotes the degradation
of HMGCR through the ubiquitin-proteasome pathway,
and therefore slows down cholesterol biosynthesis [9].
This was very important negatively feedback regulatorynd control subjects of Han population in recessive model
Men Women
OR 95% CI P OR 95% CI P
1.789 1.219–2.627 0.000* 1.024 0.604–1.736 0.929
1.058 0.97–1.154 0.2 1.152 1.021–1.299 0.021
1.098 1.038–1.161 0.000* 1.182 1.103–1.267 0.000*
1.42 1.03–1.932 0.026* 1.377 0.9–2.106 0.14
1.015 0.864–1.192 0.856 1.307 1.068–1.601 0.009*
1.842 1.197–2.834 0.005* 4.251 2.238–8.073 0.000*
1.703 1.242–2.333 0.000* 2.279 0.524–9.916 0.272
I, body mass index; Glu, glucose; LDL, low density lipoprotein.
Table 6 Pairwise linkage disequilibrium (| D’| above
diagonal and r2 below diagonal) for the three SNPs
| D’|
CAD Control
SNP SNP1 SNP2 SNP3 SNP1 SNP2 SNP3
r2 SNP1 0.965 0.961 0.99 0.99
SNP2 0.155 0.922 0.176 0.99
SNP3 0.267 0.492 0.363 0.485
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http://www.lipidworld.com/content/13/1/147mechanism that cells use to control their cholesterol
level. Sterol regulatory element-binding proteins (SREBPs)
are major transcription factors activating the expression of
genes involved in biosynthesis of cholesterol, fatty acid
and triglyceride [22]. The SREBP is first synthesized as
membrane bound transcription precursor (pre-SREBP),
which forms a complex with SREBP cleavage-activating
protein (SCAP). When cellular cholesterol level is high,
Insig-1/-2 binds SCAP and retains the SCAP-SREBP com-
plex in ER [23]. When the cholesterol level is low, SCAP
dissociates from Insig-1/-2 and escorts SREBP to Golgi to
undergo protease cleavages. The released N-terminal tran-
scriptional domain of SREBP (nSREBP) enters the nucleus
to activate transcription of genes encoding proteins in
lipid biosynthesis and uptake. Meanwhile, Insig-1 is ubi-
quitinated by gp78 and degraded, therefore creating a
rapid and convergent regulation on cholesterol biosyn-
thesis and uptake [24,25]. From this angle, degradation of
Insig-1 by gp78 should release the inhibition on SREBP
and increase the biosynthesis of lipid.
The essential function of the gp78 in the cholesterol
synthesise process was ubiquitination, that is a process
during which proteins are modified with a single ubiqui-
tin or a chain of ubiquitin monomers. It occurs through
a cascading action of E1 ubiquitin-activating enzyme, E2
ubiquitin-conjugating enzyme and then E3 ubiquitin
ligase [26]. Bao-Liang Song and his colleagues found
gp78 as the ubiquitin ligase (E3) that initiates sterol-Table 7 The distubution of haplotype in CAD patient and con
Total Men
CAD (%) Control (%) P value CAD (%
1 100 A T A 0.3 0 - 0.4
2 101 A T G 21.2 20.2 0.495 20.8
3 010 G C A 36.2 41 0.044 36.5
4 000 G T A 15.1 16.6 0.422 14.5
5 001 G T G 26.2 22.2 0.02 26.4
6 110 A C A 0 0 - 0
7 111 A C G 0.3 - - 0.3
8 011 G C G 0.7 - - 1.1
The P value of genotype was calculated by Fisher’s exact test, and revised by False
Minimum gene frequency.
The P value of each haplotype by the order of SNP1-SNP2-SNP3 is relative to the otdependent degradation of reductase, and Insig-1 as a
bridge between gp78/VCP and the reductase substrate
[11]. DeBose-Boyd and coworkers have shown that
sterols induce the binding of ER-embedded HMG CoA
reductase to Insig-1, and this interaction induces the
ubiquitination and degradation of the reductase [27].
Later, they have shown that ubiquitination is mediated
by gp78, which forms a complex with Insig-1 [11]. In
the presence of sterols, this bound gp78 ubiquitinates
HMG CoA reductase. It is tempting to speculate that in
the absence of sterols, when neither Scap nor HMG
CoA reductase is bound to Insig-1, gp78 ubiquitinates
Insig-1, accelerating its degradation. When sterols induce
HMGCoA reductase to bind to Insig-1, the ubiquitination
reaction is diverted toward HMG CoA reductase, on the
other hand, when sterols induce Scap to bind to Insig-1,
the gp78 no longer ubiquitinates Insig-1. Perhaps Scap
displaces gp78 from Insig-1 in a sterol dependent reaction
[25]. In sterol-depleted cells, cholesterol dissociates from
the Scap/SREBP complex, and this causes Insig-1 to disso-
ciates well. The liberated Insig-1 undergoes ubiquitination
by gp78 at lysines 156 and 158, which leads to proteaso-
mal degradation. The liberated Scap/SREBP complex
binds to COPII proteins, which cluster it into COPII-
coated vesicles for transport to the Golgi [28]. In the
Golgi, the SREBP is processed by proteases to release the
transcriptionally active NH2-terminal domain, which
moves to the nucleus, where it activates transcription of
all of the genes that encode enzymes required for choles-
terol synthesis and for uptake through the LDL receptor
[29]. It means that gp78 gene promotes the synthesis of
cholesterol.
In the Han population, for total and men, there was a
significant difference in the genotypic distribution of
SNP3 (rs2440472) between CAD patients and control
subjects, the distribution of SNP3 (rs2440472) alleles
and the dominant model (AA vs AG +GG) and recessive
model (GG vs AG +AA) showed a significant differencetrol participants
Women
) Control (%) P value CAD (%) Control (%) P value
0 - 0 0 -
19.7 0.52 21.8 21 0.738
42.4 0.058 35.8 38.8 0.386
17.7 0.154 16.2 15 0.619
20.2 0.005 25.9 25.2 0.816
0 - 2.34 2.02 0.354
0 - 0.3 0 -
0 - - - -
discovery rate. *P<0.05; 0 represent Maximum gene frequency, 1 represent
her haplotypes as a group (overall P =0.001).
Table 8 Genotype and allele distributions between Han and Uygur population
CAD Control
Total Men Women Total Men Women
Han n Uygur n P value Han n Uygur n P value Han n Uygur n P value Han n Uygur n P value Han n Uygur n P value Han n Uygur n P value
rs731119
(SNP1)
Genotype G/G 369 269 0.545 237 202 0.68 132 67 0.642 375 244 0.96 227 146 0.714 148 98 0.893
A/A 21 18 11 12 10 6 26 18 11 10 15 8
A/G 217 140 139 108 78 32 184 117 117 73 15 8
Allele G 955 678 0.69 613 512 0.888 342 166 0.703 934 605 0.99 571 365 0.761 363 240 0.718
A 259 176 161 132 98 44 236 153 139 93 97 60
rs2617849
(SNP2)
Genotype T/T 222 152 0.772 132 120 0.159 90 32 0.234 181 128 0.68 102 78 0.422 79 50 0.476
C/C 74 57 49 36 25 21 87 58 56 31 31 27
C/T 261 174 168 126 93 48 284 176 170 107 114 69
Allele C 409 288 0.697 266 198 0.271 143 90 0.014 458 292 0.62 282 169 0.205 176 123 0.442
T 705 478 432 366 273 112 646 432 374 263 272 169
rs2440472
(SNP3)
Genotype A/A 164 85 0.008* 110 57 0.011* 54 28 0.582 187 78 0.00* 123 43 0.00* 64 35 0.125
G/G 144 120 95 94 49 26 98 106 54 64 44 42
A/G 294 169 183 128 111 41 287 192 164 118 123 74
Allele A 622 339 0.006* 403 242 0.002* 219 97 0.979 661 348 0.00* 410 204 0.00* 251 144 0.072
G 582 409 373 316 209 93 483 404 272 246 211 158
CAD, coronary artery disease.
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http://www.lipidworld.com/content/13/1/147between CAD and control participants. G allele and the
recessive model (GG vs AG +AA) of rs2440472 was sig-
nificantly higher in CAD patients than in control partici-
pants, A allele and the dominant model(AA vs AG +
GG)of rs2440472 was significantly lower in CAD pa-
tients than in control participants. The significant differ-
ence in the two models of SNP3 between CAD patients
and control subjects was retained after adjustment for
covariates such as Glu, BMI, EH, DM, LDL and smoking
(Table 4). This indicated in Han population, for total
and males, the risk of CAD was increased with the
GG genotype of rs2440472, and the AA genotype of
rs2440472 was lowering the risk of CAD. In our study
we also identifying two susceptible haplotypes (G-T-G;
G-C-A) in the Han population, this result is consistent
with the distribution of genotype results that the GG
genotype of rs2440472 is a risk factor of CAD and the
AA genotype is a protective factor of CAD, because G
allele and A alleles of SNP3 was involved in haplotypes
001 and 010. Although, the gp78 has opposite effects on
lipid biosynthesis, but the net effect was to increase the
biosynthesis of cholesterol [13]. We speculated that Han
subjects with the GG genotype of rs2440472 (SNP3) and
G-T-G haplotype may be make the gp78 gene have a
high ability for synthesizing cholesterol, thus increasing
the chances of CAD; in contrast, that with the AA geno-
type of rs2440472(SNP3) and G-C-A haplotype may be
attenuate the synthesizing function of gp78 gene, which
was decreasing the chances of CAD. For the Uygur
population, we did not find an association between the
three SNPs of the gp78 gene and CAD. In addition, in
the Table 8 we have analysed the distribution of geno-
types and alleles of SNP1, SNP2 and SNP3 for the GP78
gene between the Han and Uygur populations. From the
table we can see both in the CAD and Control subjects
the frequency of SNP3 (rs2440472) genotypes and alleles
showed a significant difference between Han and Uygur
population. We consult the national center for biotech-
nology information (NCBI) Web site then found the
distribution of rs2440472 genotypes showed a significant
difference between the European and Asian population.
The Uygur population is one of the minorities residing
mainly in northwest China (The Xinjiang Uygur Au-
tonomous Region of China).They originate from inter-
marriage between Caucasians and Mongolians, and have
their own language culture and the unique genetic back-
ground. The Han and Uygur are two different races, they
has a different genetic background, maybe it was the
reason why the distribution of rs2440472 genotypes have
differences between the two populations.
In our study when analyzing men and women separ-
ately, there was only an association between the SNP3
(rs2440472) and CAD in men, however, in the women
we did not find any association between the three SNPsof the gp78 gene and CAD. We can’t find any report
about the gp78 gene and gender relation, so we unable
to explain why there are gender differences in the distri-
bution of genotypes, thus further studies are needed to
explore this issue.
Conclusion
This was the first demonstration of the relationship
between the gp78 gene polymorphisms and CAD. we
found that rs2440472 may be a novel polymorphism of
the gp78 gene associated with CAD in Han population
in China. The GG genotype and G allele of rs2440472 in
gp78 gene could be a risk genetic marker of CAD and
the AA genotype and A allele may be a protective gen-
etic marker of CAD in Han population in China, which
supported the hypothesis that gp78 gene variations were
involved in the pathogenesis of CAD. Certainly it needs
further studies are warranted to replicate our results as
well as elucidate the biological mechanism.
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